Related Experiment Video
Updated: Nov 11, 2025
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
Published on: July 28, 2020
Larotrectinib in a NTRK-rearranged soft tissue sarcoma in the neoadjuvant setting: A case report
Catherine Percy1, Thomas Schubert1, Christine Galant1
1Multidisciplinary Sarcoma Team Cliniques Universitaires Saint-Luc Brussels Belgium.
Abstract:
Patients with soft tissue sarcomas should be assessed for neurotrophic tropomyosin receptor kinase (NTRK) gene fusions as neoadjuvant treatment with larotrectinib may prevent amputation.
Insights
Testing for neurotrophic tropomyosin receptor kinase (NTRK) gene fusions in soft tissue sarcoma patients is crucial. Early larotrectinib treatment may help avoid limb amputation.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Soft tissue sarcomas are a diverse group of cancers.
- Identifying specific genetic alterations can guide treatment strategies.
- Neurotrophic tropomyosin receptor kinase (NTRK) gene fusions are rare but actionable oncogenic drivers.
Observation:
- Patients with soft tissue sarcomas may harbor NTRK gene fusions.
- Larotrectinib is a targeted therapy effective against NTRK fusions.
Findings:
- The presence of NTRK gene fusions in soft tissue sarcomas indicates potential benefit from larotrectinib therapy.
- Neoadjuvant larotrectinib treatment has shown promise in managing these tumors.
Implications:
- Genomic assessment for NTRK fusions should be standard for soft tissue sarcoma patients.
- Targeted therapy with larotrectinib may represent a limb-sparing treatment option.
- This approach could improve patient outcomes and quality of life.
More Related Videos
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
07:30Electromagnetic Navigation Transthoracic Nodule Localization for Minimally Invasive Thoracic Surgery
Published on: May 4, 2022